Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study (Q34485373)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

title

Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

main subject

biomarker

0 references

author

Andreas Schneeweiss

series ordinal

1

object named as

Andreas Schneeweiss

0 references

author name string

Stephen Chia

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

Roberto Hegg

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

Christoph Tausch

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

Rahul Deb

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

Jayantha Ratnayake

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

Virginia McNally

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

Graham Ross

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

Astrid Kiermaier

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

Javier Cortés

series ordinal

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

publication date

8 July 2014

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

published in

Breast Cancer Research

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

volume

16

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

issue

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

page(s)

R73

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

cites work

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

6 July 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

6 July 2018

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

6 July 2018

Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

6 July 2018

Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

6 July 2018

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

6 July 2018

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

6 July 2018

Utility of serum HER2 extracellular domain assessment in clinical decision making: pooled analysis of four trials of trastuzumab in metastatic breast cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

6 July 2018

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

6 July 2018

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

6 July 2018

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

6 July 2018

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

6 July 2018

Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

6 July 2018

Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

6 July 2018

Role of HER2 gene overexpression in breast carcinoma

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

6 July 2018

p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1186%2FBCR3690

retrieved

21 January 2018

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1186%2FBCR3690

retrieved

21 January 2018

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1186%2FBCR3690

retrieved

21 January 2018

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

27 October 2018

Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.

1 reference

stated in

PubMed Central

reference URL

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226982

retrieved

27 October 2018

Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1186%2FBCR3690

retrieved

21 January 2018

Identifiers

DOI

10.1186/BCR3690

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

Dimensions Publication ID

1053276062

0 references

PMC publication ID

4226982

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

PubMed publication ID

25005255

1 reference

stated in

Europe PubMed Central

PubMed publication ID

25005255

retrieved

2 August 2017

ResearchGate publication ID

263777430

0 references

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34485373&oldid=2196695807"